Ab#4506 ASCO #ASCO25 by Toni Choueiri, MD👉bit.ly/3H57gZC👉Results from Ph 1 ARC-20 study #kidneycancer👉Casdatifan + Cabo has promising activity (manageable AEs) in pts w/ previously treated RCC👇#AlexandraDrakaki OncoAlert UroToday.com @KidneyCAN Kidney Cancer

Finding a Hematology/Oncology Job in the United States on a J-1 Visa While Pursuing Your Career Goals | ASCO Connection connection.asco.org/do/finding-hem… @asco #asco25 @glopesmd

It’s only Saturday of #ASCO25 and my ❤️ is full!! Thank you ASCO for this honor, congrats to all awardees! And I am just so happy to be with my people! So honored to have received #FASCO today, and be able to share it with so many dear colleagues and friends. It’s an honor to

CtDNA exploratory analysis from NIAGARA by Tom Powles #ASCO25 👨‍🔬 CtDNA + decreased after neoadjuvant chemo and prior to cystectomy 🧬 CtDNA - is favorable prognostic factor 🧹 Better outcomes with CtDNA clearance than persistence 🔪 CtDNA + post-cystectomy = poor prognosis

Casdatifan, a nivel HIF2alpha inhibitor, on combination with cabozantinib shows promising response rate in pretreated metastatic RCC patients #ASCO25 @asco #FeaturedVoices OncoAlert Toni Choueiri, MD SEOM

#ASCO25 HIF inhibitor combination results. Shown below is single agent Cabo and Belzu for reference, and published HIF-based combo data. *ORR marginally higher *PFS longer but endpoint not reliable in a single-arm trial *Phase 3 trials are planned. Beating TKI may be challenging

Our contemporary "negative" RCTs in metastatic UC are just not the same as our "negative" RCTs of the past. Granted a small subset -- but this is durable disease free survival OFF treatment after Ipi + Nivo #CM901. #MedIQASCO25 #ASCO25 #bladdercancer.

🧪Exciting science in GU - Kidney & Bladder at #ASCO25! Don’t miss these cutting-edge posters on: ✅Novel immuno + targeted combos ✅OxPhos metabolism ✅QOL & real-world data ✅CAR T-cell therapy in ccRCC Featuring work lisaderosa Alex Chehrazi-Raffle, MD Benjamin L Maughan Shilpa Gupta Sumanta K. Pal, MD, FASCO ..

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

I’ve been in the exercise oncology field for 20 years and for all of that time, the main criticism has been “show me a well controlled RCT.” Well, here it is. Exercise following adjuvant chemotherapy for colon cancer reduced recurrence and improves OVERALL SURVIVAL! #ASCO25

IMO the most important message here is the importance of paying attention to CV dz for men with advanced PC. Our must do checklist for men with advanced PC should include: 1) Germline + somatic NGS 2) Manage CV health 3) Manage Bone health

Early phase IIT to suggest favorable outcome with Taxol/CPI in UC. Kudos to Rohan Garje, MD for putting this IIT as 3rd year fellow UI Holden Comprehensive Cancer Center now GU leader Miami Cancer Institute Research and to #Aditya current fellow University of Iowa Health Care for closing the loop with pub sciencedirect.com/science/articl…

Excellent work from Anirban Kundu (Ph.D.) previously my UAB Medicine colleague now a rising ⭐️ UniversityofArizona , novel 🎯 in #RCC .

Today, Mayo Clinic opened the Duan Family Building, taking another step in our journey to introduce carbon ion therapy for patients in the Americas. This revolutionary treatment will enhance our ability to treat aggressive cancers. Learn more: mayocl.in/4mYTVme

Tumor informed 🧬 #ctDNA #MRD high concordance with outcomes in #penileCA and #urethralCA , amazing work from rising 🌟 Kartik Patel UAB Urology working with Chas Peyton . UAB O'Neal Comprehensive Cancer Center UAB Medicine - so more to come from this group!

Air pollution harms our patients. U.S. EPA plans to roll back climate and clean air protections—time to speak up. Signing this letter Oncology Advocates United for Climate and Health Dr. Joan Schiller Lung Health Foundation takes seconds but shows we stand by our value_ docs.google.com/forms/d/e/1FAI…

1/ Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet? If you work in pathology or oncology, you’ve likely come across Ki-67 many times. But where does the name come from? A short 🧵 on the origins, function, and significance of Ki-67.

A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist. #BladderCancer #Oncology #Immunotherapy Matt Galsky Leslie Ballas Ashish M. Kamat, MD, MBBS ASCO Journal of Clinical Oncology World Bladder Cancer Patient Coalition OncoAlert Oncology Brothers Uromigos International Urology Cancer Summit doi.org/10.1200/JCO-25…

Honored to co-chair IKCS25 in Denver CO with Sarah P. Psutka MD MS manojkumar , abst deadline Aug15, great agenda put together with Qing Zhang Stephanie Berg Chad Tang, MD #MCarlo #DGeynisman Salvatore La Rosa Kidney Cancer plz submit abst kidneycancer.org/event/2025-ikc…

JUST IN: (+) Phase 3 KEYNOTE-905 trial in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC): EV+Pembro shows an EFS, pCR and OS benefit compared to radical cystectomy alone. a Potential new SOC (again). cc: BioSpace biospace.com/press-releases…